Episodes
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt covers three key updates in oncology. A new analysis shows that radiation oncology practices are consolidating rapidly, raising concerns about access to care, patient choice, and job stability for oncologists. In breast cancer, a randomized trial finds that hand cooling and compression can significantly reduce chemotherapy-induced neuropathy, offering a simple, cost-effective strategy to protect patientsâ nerves. And finally, the EMA has recommended expanding nivolumab plus ipilimumab for advanced hepatocellular carcinoma, positioning it as an alternative to the current standard of care. Tune in for the latest insights shaping cancer treatment.
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt covers three important topics shaping cancer care. A new study confirms that achieving MRD negativity early in AML is critical for long-term survival, reinforcing MRDâs growing role in treatment decisions. We then explore the hard truth about early-phase cancer trials, revealing that only 16.2% of phase 2 treatments ever gain FDA approvalâwhat does this mean for patients enrolling in these studies? Finally, we examine the rapid expansion of Hospital-at-Home care, a model that could change oncology treatment, but also raises concerns about patient safety and healthcare equity. Tune in for the latest updates and insights.
-
Episodes manquant?
-
In this episode of Curie, Matt covers three major developments in oncology. The FDA has approved datopotamab deruxtecan (Datroway) for HR positive, HER2 negative breast cancer, marking a new era for antibody-drug conjugates in this disease. A meta-analysis suggests that the timing of immunotherapy infusions may impact survival outcomes, raising questions about how circadian rhythms influence treatment response. Finally, a global analysis confirms that early-onset colorectal cancer is on the rise worldwide, challenging current screening guidelines and prompting discussions on prevention strategies. Tune in for the latest insights shaping cancer care.
-
In this episode of Curie, Matt breaks down three major updates in oncology. ASCO has released updated guidelines for advanced ovarian cancer, emphasizing primary cytoreductive surgery over neoadjuvant chemotherapy when feasible. The Mammo-50 trial challenges the standard of annual mammographic surveillance for breast cancer survivors over 50, showing that less frequent screening is non-inferior. Finally, the eNRGy trial confirms the efficacy of zenocutuzumab in treating NRG1 fusion-positive cancers, a rare but actionable oncogenic driver in NSCLC and pancreatic cancer. Tune in for expert insights into how these findings are shaping cancer care.
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt covers three major updates in oncology. Vimseltinib (Romvimza) has been FDA-approved for tenosynovial giant cell tumors (TGCT), providing a new non-surgical option for symptomatic patients. Sotorasib plus panitumumab is now approved for KRAS G12C-mutated colorectal cancer, marking a breakthrough in targeted therapy for this hard-to-treat population. Finally, two phase III trials show that adding immunotherapy to neoadjuvant chemotherapy improves pathological complete response rates in high risk ER positive, HER2 negative breast cancerâa potential paradigm shift in treatment. Tune in for the latest updates in precision oncology!
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt breaks down three critical updates in oncology. A new study links declining PSA screening rates to a rise in advanced prostate cancer cases, raising questions about early detection guidelines. We then explore new findings on brain metastases in HER2 positive breast cancer, revealing how patients with CNS only disease have significantly better outcomes than those with extracranial spread. Finally, the FDA has approved subcutaneous nivolumab, offering a faster, more convenient immunotherapy option for multiple cancers. Tune in for the latest insights shaping cancer care!
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt explores game-changing developments in oncology. Learn about the latest chemotherapy-free approach for HER2-mutated metastatic breast cancer, where tucatinib and trastuzumab are showing durable responses. Discover how datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, is offering new hope for EGFR-mutated and ALK-rearranged NSCLC patients. Finally, dive into groundbreaking insights on FGFR inhibitor resistance in cholangiocarcinomaâand how liquid biopsies could revolutionize treatment strategies. Stay informed and ahead of the curve with these cutting-edge updates in precision oncology!
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
From nivolumab-plus-ipilimumab in colorectal cancer to the latest CAR-T therapies in GI malignancies, explore the cutting-edge breakthroughs from ASCO GI 2025. This episode covers transformative data thatâs reshaping the future of GI oncology.
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt explores the latest breakthroughs and challenges in oncology care. Learn about novel immunotherapy combinations offering new hope for advanced melanoma patients. Dive into long-term findings solidifying trastuzumab emtansine (T-DM1) as the gold standard for certain HER2-positive breast cancer cases. Finally, discover how financial barriers are impacting patientsâ access to life-saving cancer treatmentsâand what oncologists can do about it. Stay informed and inspired with these essential updates!
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt uncovers the nuanced relationship between red wine and cancer risk, separating myths from evidence. We then dive into the promising NECTORS approach for HPV-related head and neck cancer, offering a less toxic alternative to standard care. Finally, learn how metronomic capecitabine is reshaping breast cancer treatment with an effective and cost-efficient option. Stay ahead with these critical insights in oncology!
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt explores the latest in oncology. Discover how cetuximab outperformed immunotherapy in head and neck cancer, easing treatment decisions for cisplatin-ineligible patients. Learn about new findings that dispel fears of a link between eosinophilic esophagitis (EoE) and esophageal cancer. Finally, dive into the promising results for imlunestrant, an oral SERD poised to transform breast cancer care. Stay informed with these critical updates!
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt delves into three groundbreaking developments. Discover how MRI-guided SBRT is transforming prostate cancer care with fewer side effects. Learn about the FDAâs approval of zanidatamab, a promising therapy for HER2-positive biliary tract cancer. Finally, explore new research highlighting sex-specific risks in MASLD and what it means for patient care. Stay informed on the latest advances in oncology!
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
Join us as we wrap up ASH 2024, highlighting transformative breakthroughs like menin inhibitors in AML, advancements in gene editing for sickle cell disease, and game-changing data in CAR-T therapies. Explore whatâs shaping hematologyâs future.
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
On Day 4 of ASH 2024, explore the remarkable 96% disease-free survival with Blincyto in pediatric ALL, deep responses with Epcoritamab in relapsed CLL, and the promise of a next-gen BCL2 inhibitor in a potent CLL combination. Tune in for transformative insights!
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
Day 3 of ASH 2024 revealed groundbreaking findings: a 97% complete response rate for zilovertamab vedotin in diffuse large B-cell lymphoma, new insights into zanubrutinibâs efficacy in chronic lymphocytic leukemia, and promising survival data for belantamab mafodotin in multiple myeloma.
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
On Day 2 of ASH 2024, we explore breakthroughs in treating high-risk smoldering multiple myeloma, advancements in chronic lymphocytic leukemia therapies, and a revealing study on leukemia risk in Ground Zero first responders. Stay updated with insights that are reshaping hematology practice.
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
Dive into Day 1 of ASH 2024 with Curie. In this episode, we discuss key takeaways from groundbreaking studies, including etavopivatâs promising results for sickle cell disease, rilzabrutinibâs potential to transform ITP treatment, and hydroxyureaâs expanded use for managing HbSC.
-
Prepare for ASH 2024 with this in-depth preview! In this episode, Matt dives into the conferenceâs overarching themes, from artificial intelligence and cellular therapies to health equity and novel drug advancements. He also shares practical tips to help you make the most of the event.
Hereâs a list of the key sessions and presenters mentioned in this episode:
The Application of Artificial Intelligence in Hematological Diagnostics with Dr. Claudia Haferlach.The Role of Artificial Intelligence in Hematology Practice: The Good, the Bad, and the Ugly with Dr. Alex Hoyer and Dr. Maria Santos.BCMA-Targeted CAR-T Therapies in Multiple Myeloma presented by Dr. Sarah Lentzsch.Updates on CD19 CAR-T Therapies for CLL with Dr. William Wierda.Gamma-Delta T-Cell Therapies for Hematologic Malignancies by Dr. Anne Vincent.Reducing Disparities in Clinical Trials with Dr. Paul James.Bridging Language Gaps in Hematology with Dr. Amara Green.Advances in molecular glues for sickle cell disease with Dr. Emily Rychak.Updates on Menin Inhibitors in High-Risk Leukemia by Dr. Peter Lang.AMPLIFY Trial Results on BTK Inhibitors for CLL presented by Dr. Anas Younes.Bristol Myers Squibbâs Five-Year Survival Data for Breyanzi in Large B-Cell Lymphoma with Dr. Jeremy Abramson.Findings from the CA057-003 Trial on Mezigdomide for Relapsed and Refractory Multiple Myeloma by Dr. Luciano Costa.Long-term outcomes of Luspatercept in Beta-Thalassemia shared by Dr. Khaled Musallam.
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
Join us as we unpack the debate on breast cancer screening guidelines, explore PI3K inhibitors in advanced breast cancer, and examine AIâs role in rare cancer diagnostics.
-
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platformâoffering in-depth analysis, timely insights, and discussions tailored for medical professionals.
Dr. Goldfarb, your request led us to this deep dive into the evolving treatment landscape of rectal cancer. In this episode of Ask Curie, we explore non-operative management strategies, the role of immunotherapy, and how biomarker-driven care is transforming clinical decision-making. We break down key findings, including the growing viability of the âwatch-and-waitâ approach, short-course vs. long-course radiation therapy, and emerging targeted therapies like checkpoint inhibitors for MSI-high tumors. Should oncologists be reconsidering surgery-first approaches? And what does the latest data say about de-escalating treatment without compromising outcomes? Tune in for an evidence-based look at the future of rectal cancer treatment.
